SignalXSignalX

AMLX Amylyx Pharmaceuticals, Inc.

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Amylyx Pharmaceuticals, Inc. Overview

Amylyx Pharmaceuticals, Inc. (AMLX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New tax law impact from the One Big Beautiful Bill Act (OBBBA) signed July 4, 2025, altering R&D expense capitalization and deductions
  • • Most material update: cessation of RELYVRIO/ALBRIOZA sales after Phase 3 PHOENIX failure, eliminating prior $380.8M 2023 revenue source
+3 more insights

Get deeper insights on Amylyx Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.